See more : TrustCo Bank Corp NY (TRST) Income Statement Analysis – Financial Results
Complete financial analysis of Greenwich LifeSciences, Inc. (GLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenwich LifeSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DCM Limited (DCM.BO) Income Statement Analysis – Financial Results
- ChenGuang Biotech Group Co., Ltd. (300138.SZ) Income Statement Analysis – Financial Results
- Upstart Holdings, Inc. (UPST) Income Statement Analysis – Financial Results
- RenuEn Corporation (RENU) Income Statement Analysis – Financial Results
- The Liberty Braves Group (BATRA) Income Statement Analysis – Financial Results
Greenwich LifeSciences, Inc. (GLSI)
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.70M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| General & Administrative | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Cost & Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Interest Income | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.33M | -8.04M | -4.60M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -215.02K | -27.37K | -832.00 | 3.00 | -157.53K | 3.00 |
| Net Income | -8.89M | -7.61M | -4.54M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
| Weighted Avg Shares Out (Dil) | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
Why Greenwich LifeSciences Stock Tanked Today
The drop came despite the clinical-stage biotech announcing good news over the weekend.
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Why Greenwich LifeSciences Stock Is Rising Today
The company reported positive data for its cancer immunotherapy candidate GP2.
What's Going On With GLSI Stock And PSMT Stock Today?
Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by more than 15% after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0% metastatic breast cancer recurrences over five years...
Greenwich LifeSciences Stock Price Increased Over 20% Pre-Market: Why It Happened
The stock price of Greenwich LifeSciences (NASDAQ: GLSI) increased by over 20% pre-market. This is why it happened.
Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up
Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting. The company plans to publish the poster, the abstract, and an audio recording tomorrow in a...
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
STAFFORD, Texas--(BUSINESS WIRE)--GLSI Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years Follow-up
Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy
Greenwich LifeSciences is advancing cancer treatments with life-changing potential, and recent developments should boost GLSI stock's value. The post Greenwich LifeSciences Is Both a Sound Investment and a Feel-Good Buy appeared first on InvestorPlace.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI
New York, New York--(Newsfile Corp. - March 24, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/greenwich-lifesciences-inc-information-request-formor contact Joseph E....
Source: https://incomestatements.info
Category: Stock Reports